Clinical Trial #G-0261:
- Comparison study of two accepted chemotherapy options for women with uterine cancer that has returned.
- The recurrence must be newly diagnosed with measurable disease greater than 1 centimeter. Prior adjuvant radiation is allowed. Hormonal therapy must be discontinued.
- Exclusions include, but are not limited to: Prior chemotherapy for uterine sarcoma, no planned radiotherapy after chemotherapy and participant can not have a hypersensitivity to filgrastim.